Dietary Intervention for Control of Clinical Symptom in Patients with Systemic Metal Allergy: A Single Center Randomized Controlled Clinical Study
In conclusion, dietary intervention by a registered dietitian is effective in improving skin symptoms with a reduction in metal intake.PMID:38379275 | DOI:10.24546/0100486230 (Source: Kobe J Med Sci)
Source: Kobe J Med Sci - February 21, 2024 Category: General Medicine Authors: Reiko Mikajiri Atsushi Fukunaga Makoto Miyoshi Noriaki Maeshige Ken Washio Taro Masaki Chikako Nishigori Ikuko Yamamoto Akiyo Toda Michiko Takahashi Shun-Ichiro Asahara Yoshiaki Kido Makoto Usami Source Type: research
Dietary Intervention for Control of Clinical Symptom in Patients with Systemic Metal Allergy: A Single Center Randomized Controlled Clinical Study
In conclusion, dietary intervention by a registered dietitian is effective in improving skin symptoms with a reduction in metal intake.PMID:38379275 | DOI:10.24546/0100486230 (Source: Kobe J Med Sci)
Source: Kobe J Med Sci - February 21, 2024 Category: General Medicine Authors: Reiko Mikajiri Atsushi Fukunaga Makoto Miyoshi Noriaki Maeshige Ken Washio Taro Masaki Chikako Nishigori Ikuko Yamamoto Akiyo Toda Michiko Takahashi Shun-Ichiro Asahara Yoshiaki Kido Makoto Usami Source Type: research
Examining allergy related diseases in Africa: A scoping review protocol
by Max Yang Lu, Nadia Shobnam, Alicia A. Livinski, Sarini Saksena, Dylan Salters, Michelle Biete, Ian A. Myles
During recent decades, allergy related diseases have emerged as a growing area of concern in developing regions of the world, including Africa. Worldwide prevalence of allergic diseases has grown to an estimated 262 million for asthma, 400 million for allergic rhinitis (or hay fever), 171 million with atopic dermatitis (or eczema), and over 200 million for food allergy. In Africa, considerable variability exists in the data surrounding prevalence at the continent-wide, regional, and study site levels. Furthermore...
Source: PLoS One - February 20, 2024 Category: Biomedical Science Authors: Max Yang Lu Source Type: research
Dupilumab to treat chronic palmoplantar eczema: a retrospective multicenter cohort study
Actas Dermosifiliogr. 2024 Feb 17:S0001-7310(24)00141-8. doi: 10.1016/j.ad.2023.12.006. Online ahead of print.NO ABSTRACTPMID:38373606 | DOI:10.1016/j.ad.2023.12.006 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - February 19, 2024 Category: Dermatology Authors: J Magdaleno Tapial A Torrijos Aguilar V Gonz ález Delgado P Hern ández Bel Source Type: research
Dupilumab to treat chronic palmoplantar eczema: a retrospective multicenter cohort study
Actas Dermosifiliogr. 2024 Feb 17:S0001-7310(24)00141-8. doi: 10.1016/j.ad.2023.12.006. Online ahead of print.NO ABSTRACTPMID:38373606 | DOI:10.1016/j.ad.2023.12.006 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - February 19, 2024 Category: Dermatology Authors: J Magdaleno Tapial A Torrijos Aguilar V Gonz ález Delgado P Hern ández Bel Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Derm Venereol A... - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Derm Venereol A... - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Dermato-Venereologica - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Dermato-Venereologica - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Derm Venereol A... - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Dermato-Venereologica - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
Acta Derm Venereol. 2024 Feb 12;104:adv13467. doi: 10.2340/actadv.v104.13467.ABSTRACTIn young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moderate-to- severe AD receiving dupilumab or placebo, plus low-potency topical corticosteroids. Post hoc analyses were performed on the full analysis set (FAS) and a subset of patients with Investigator's Global Assessment score > 1 at week 16. T...
Source: Acta Derm Venereol A... - February 13, 2024 Category: Dermatology Authors: Michael J Cork Benjamin Lockshin Andreas Pinter Zhen Chen Brad Shumel Randy Prescilla Source Type: research
Age-specific Metabolomic profiles in children with food allergy
CONCLUSIONS: FA children of different ages manifest unique metabolic changes which may reflect at least in part pathogenic mechanisms and environmental influences operative at different time points in the disease course.PMID:38336145 | DOI:10.1016/j.clim.2024.109928 (Source: Clinical Immunology)
Source: Clinical Immunology - February 9, 2024 Category: Allergy & Immunology Authors: E Crestani M Benamar W Phipatanakul R Rachid T A Chatila Source Type: research
Development of a Patient Journey Map for Improving Patient Experience and Quality of Atopic Dermatitis Care
ConclusionThe severity of AD has a profound impact on patients' lives. Patient and caregiver emotional and social needs can be met by adequate communication, access to effective treatments and comprehensive psychological support. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 9, 2024 Category: Dermatology Source Type: research
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.PMID:38323500 | PMC:PMC10863496 | DOI:10.2340/actadv.v104.19454 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - February 7, 2024 Category: Dermatology Authors: Esm é Kamphuis Celeste M Boesjes Laura Loman Marijke Kamsteeg Inge Haeck Anneke M T Van Lynden-van Nes Klaziena Politiek Liana F Van der Gang Marlies De Graaf Marjolein S De Bruin-Weller Marie L A Schuttelaar Source Type: research
